Register
Login:
Share:
Email Facebook Twitter

Caps Lock on… DAVID LENIGAS on this week’s Share Views!! Watch here

Share Views Episode 10 - DAVID LENIGAS talks Gatwick Gusher and AAAP


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 139.50Bid: 0.00Ask: 0.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 0.00Spread as %: 0.00%Open: 132.50High: 0.00Low: 0.00Yesterday’s Close: 139.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
139.50

Share Price SpacerBid
0.00

Share Price SpacerAsk
0.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
0

Share Price SpacerOpen
132.50

Share Price SpacerHigh
0.00

Share Price SpacerLow
0.00

Share Price SpacerClose
139.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.48m £85.77m 2,000

52 Week High 157.50 52 Week High Date 26-SEP-2016
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1 0 0 -4.810 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

29-Sep-16
18:01:13
139.50
2,500
 
0.00
0.00
3,488
Trade Type:
Ordinary
Bargain conditions apply

27-Sep-16
14:37:22
144.7498
100,000
Buy* 
136.00
143.00
144.75k
Trade Type:
Ordinary

29-Sep-16
17:09:32
139.50
2,500
 
136.00
143.00
3,488
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Thu 17:48TrollHunter2RE: Sarepta....NOooooo!!!!139.50No Opinion
Another thought Ego, we are already partnered with BMS on the SEGLIN portfolio, maybe they are one of the several interested parties!
It's worth a read of their partnering page and they are flush with cash!
Thu 17:37pomanderRE: Sarepta....NOooooo!!!!139.50No Opinion
There's always interested parties and every CEO believes he has the best drug.

Sorry to burst your bubble but Glyn won't get VC funding in the City (what a dated phrase) they don't fund high risk pharma's with no revenue streams and if they did they would want a huge chunk of equity.

Funding would have to come from a collaboration of some sort, most likely with a large pharma company, or a Placing.

Time to come back to the real world and not the land of make believe.
Thu 17:26TrollHunter2RE: Sarepta....NOooooo!!!!139.50No Opinion
Absolutely Ego, it really doesn't matter what price you buy at around these level in my opinion.
If you've done your research, and am prepared to take the gamble on this little biotech delivering what it potentially could, then any stock bought at these prices will give you a very very good return.

Before a placing we need to answer the RDZ deal question. But if the answer is that it cannot be done at fair value right now then I get the impression many current PI's would be happy with a… Read More
Thu 16:56egomonkeyRE: Sarepta....NOooooo!!!!139.50No Opinion
Actually Monday's top-up doesn't look so bad now :) My view was and is that we don't necessarily need news to see SP growth - just more people digging into the numbers - so the more we are discussed in the same breath as Sarepta the better.

I'm also not overly concerned about funding, because barring a complete catastrophe it's going to happen one way or another. Even a highly dilutive placement means very little if the drug works.

My average is still something like £1.60 - My… Read More
Thu 16:53English_ParisienRE: Take a Deep Breath139.50No Opinion
You are most definitely entitled to your view and I welcome it because it keeps matters level and balanced

It's just a question of delivery and encouraging some open discussion rather than scathing attacks back and forth that contribute zero in terms of helping investors become more informed on their investments

I share your concern over funding. I don't have any further money to invest currently ... so I am just sitting here and hoping that it will come good

And yes ... the report… Read More
Thu 16:51TrollHunter2Holding up nicely139.50No Opinion
now we seem to have positive news flow both from the company and around the company.

The conference next week might generate some more upward momentum but it's nice to see the price holding up now and volume increasing both here and the US.

Interesting view on the other board that NASDAQ holds down while AIM comes to a close and then rises after... let's see how it plays out this evening. GLA

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.